The story on our little gem is getting very simple:
1. An independent group in Japan has shown blood filttration increases HepC cure rates.
2. we know our filtration approach is more efficient than the other group's product and they are alrteady going commercial.
3. We are close to having commercial production up and running and have clear and strong name recognitiion in India, which is our first target for commercialization.
4. We are talking to potential strategicv partners and one of them is close enough to us that THEY told US about the Japan data, clearly increasing the market value of our company.
Yes, it is stilll possible we could go broke and not make it, but the odds have to be very low at this point.
News 
Market Data 
Discover 
AI
